Kiora Pharmaceuticals names Keith Lane as EVP of Clinical Development and Regulatory Affairs
The ophthalmology-focused hire, effective September 8, 2026, comes with a $350,000 base salary and a stock option grant of up to 55,000 shares.
SEC filing
Latest
3 stories
Tuesday, September 8
Wednesday, August 19
Kiora licenses South Korean rights to KIO-301 to Chong Kun Dang
The deal gives Kiora a $1 million upfront payment plus potential milestones and royalties as CKD takes on ophthalmic development in South Korea.
SEC filing
Friday, August 7
Kiora reports Q2 2026 results, advances KIO-301 and KIO-104 trials
Kiora moved both retinal disease programs into higher-dose enrollment and said cash on hand should fund operations into late 2028.
SEC filing